A double-blind, randomised, placebo-controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF1 antagonists GSK561679 and GW876008 on meal induced cortisol responses in patients with IBS.

Trial Profile

A double-blind, randomised, placebo-controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF1 antagonists GSK561679 and GW876008 on meal induced cortisol responses in patients with IBS.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2015

At a glance

  • Drugs Emicerfont (Primary) ; Verucerfont (Primary)
  • Indications Irritable bowel syndrome
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 18 Jan 2008 Status changed from initiated to discontinued. Updated from ClinicalTrials.gov.
    • 13 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top